ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease.
Journal
Nature aging
ISSN: 2662-8465
Titre abrégé: Nat Aging
Pays: United States
ID NLM: 101773306
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
09
11
2020
accepted:
28
04
2021
medline:
1
6
2021
pubmed:
1
6
2021
entrez:
28
4
2023
Statut:
ppublish
Résumé
Alzheimer's disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of AADvac1, an active peptide vaccine designed to target pathological tau in AD (EudraCT 2015-000630-30). Eleven doses of AADvac1 were administered to patients with mild AD dementia at 40 μg per dose over the course of the trial. The primary objective was to evaluate the safety and tolerability of long-term AADvac1 treatment. The secondary objectives were to evaluate immunogenicity and efficacy of AADvac1 treatment in slowing cognitive and functional decline. A total of 196 patients were randomized 3:2 between AADvac1 and placebo. AADvac1 was safe and well tolerated (AADvac1 n = 117, placebo n = 79; serious adverse events observed in 17.1% of AADvac1-treated individuals and 24.1% of placebo-treated individuals; adverse events observed in 84.6% of AADvac1-treated individuals and 81.0% of placebo-treated individuals). The vaccine induced high levels of IgG antibodies. No significant effects were found in cognitive and functional tests on the whole study sample (Clinical Dementia Rating-Sum of the Boxes scale adjusted mean point difference -0.360 (95% CI -1.306, 0.589)), custom cognitive battery adjusted mean z-score difference of 0.0008 (95% CI -0.169, 0.172). We also present results from exploratory and post hoc analyses looking at relevant biomarkers and clinical outcomes in specific subgroups. Our results show that AADvac1 is safe and immunogenic, but larger stratified studies are needed to better evaluate its potential clinical efficacy and impact on disease biomarkers.
Identifiants
pubmed: 37117834
doi: 10.1038/s43587-021-00070-2
pii: 10.1038/s43587-021-00070-2
doi:
Substances chimiques
tau Proteins
0
AADvac1
0
Biomarkers
0
Banques de données
EudraCT
['2015-000630-30']
Types de publication
Randomized Controlled Trial
Multicenter Study
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-534Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
pubmed: 1759558
doi: 10.1007/BF00308809
Wischik, C. M. et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85, 4506–4510 (1988).
pubmed: 3132715
pmcid: 280459
doi: 10.1073/pnas.85.12.4506
Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913–4917 (1986).
pubmed: 3088567
pmcid: 323854
doi: 10.1073/pnas.83.13.4913
Whitwell, J. L. et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. Lancet Neurol. 11, 868–877 (2012).
pubmed: 22951070
pmcid: 3490201
doi: 10.1016/S1474-4422(12)70200-4
Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381 (2012).
pubmed: 22487856
doi: 10.1097/NEN.0b013e31825018f7
Murray, M. E. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain 138, 1370–1381 (2015).
pubmed: 25805643
pmcid: 4407190
doi: 10.1093/brain/awv050
La Joie, R. et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aau5732 (2020).
Mattsson-Carlgren, N. et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology 94, e2233–e2244 (2020).
pubmed: 32398359
pmcid: 7357296
doi: 10.1212/WNL.0000000000009485
Braak, H. & Del Tredici, K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 121, 171–181 (2011).
pubmed: 21170538
doi: 10.1007/s00401-010-0789-4
Franzmeier, N. et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease. Nat. Commun. 11, 347 (2020).
pubmed: 31953405
pmcid: 6969065
doi: 10.1038/s41467-019-14159-1
Vasili, E., Dominguez-Meijide, A. & Outeiro, T. F. Spreading of α-synuclein and tau: a systematic comparison of the mechanisms involved. Front. Mol. Neurosci. 12, 107 (2019).
pubmed: 31105524
pmcid: 6494944
doi: 10.3389/fnmol.2019.00107
Zilka, N., Korenova, M. & Novak, M. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Acta Neuropathol. 118, 71–86 (2009).
pubmed: 19238406
doi: 10.1007/s00401-009-0499-y
Rauch, J. N. et al. LRP1 is a master regulator of tau uptake and spread. Nature 580, 381–385 (2020).
pubmed: 32296178
pmcid: 7687380
doi: 10.1038/s41586-020-2156-5
Holmes, B. B. et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, E3138–E3147 (2013).
pubmed: 23898162
pmcid: 3746848
doi: 10.1073/pnas.1301440110
Mudher, A. et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol. Commun. 5, 99 (2017).
pubmed: 29258615
pmcid: 5735872
doi: 10.1186/s40478-017-0488-7
Colin, M. et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol. 139, 3–25 (2020).
pubmed: 31686182
doi: 10.1007/s00401-019-02087-9
Aoyagi, A. et al. Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aat8462 (2019).
Brunello, C. A. et al. Mechanisms of secretion and spreading of pathological tau protein. Cell. Mol. Life Sci. 77, 1721–1744 (2020).
pubmed: 31667556
doi: 10.1007/s00018-019-03349-1
Jadhav, S. et al. A walk through tau therapeutic strategies. Acta Neuropathol. Commun. 7, 22 (2019).
pubmed: 30767766
pmcid: 6376692
doi: 10.1186/s40478-019-0664-z
Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399–415 (2018).
pubmed: 29895964
pmcid: 6463489
doi: 10.1038/s41582-018-0013-z
Dingman, R. & Balu-Iyer, S. V. Immunogenicity of protein pharmaceuticals. J. Pharm. Sci. 108, 1637–1654 (2019).
pubmed: 30599169
doi: 10.1016/j.xphs.2018.12.014
Kontsekova, E. et al. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease. Alzheimers Res. Ther. 6, 45 (2014).
pubmed: 25478018
pmcid: 4255369
doi: 10.1186/alzrt277
Weisova, P. et al. Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathol. Commun. 7, 129 (2019).
pubmed: 31391090
pmcid: 6685285
doi: 10.1186/s40478-019-0770-y
Zilkova, M. et al. Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. Acta Neuropathol. Commun. https://doi.org/10.1186/s40478-020-00948-z (2020).
Kontsekova, E. et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res. Ther. 6, 44 (2014).
pubmed: 25478017
pmcid: 4255368
doi: 10.1186/alzrt278
Novak, P. et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16, 123–134 (2017).
pubmed: 27955995
doi: 10.1016/S1474-4422(16)30331-3
Novak, P. et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res. Ther. 10, 108 (2018).
pubmed: 30355322
pmcid: 6201586
doi: 10.1186/s13195-018-0436-1
Fagerland, M. W., Lydersen, S. & Laake, P. Recommended confidence intervals for two independent binomial proportions. Stat. Methods Med. Res. 24, 224–254 (2015).
pubmed: 21996567
doi: 10.1177/0962280211415469
de Wolf, F. et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain 143, 1220–1232 (2020).
pubmed: 32206776
pmcid: 7174054
doi: 10.1093/brain/awaa054
Lang, A., Weiner, M. W. & Tosun, D. O4-04-01: what can structural MRI tell about A/T/N staging? Alzheimers Dement. 15, P1237–P1238 (2019).
doi: 10.1016/j.jalz.2019.06.4758
Tosun, D. et al. Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann. Neurol. 74, 188–198 (2013).
pubmed: 23686534
pmcid: 4603555
Tosun, D. et al. Multimodal MRI-based imputation of the Aβ
pubmed: 24729983
pmcid: 3981105
doi: 10.1002/acn3.40
Bateman, R. J. et al. The DIAN-TU next generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8–19 (2017).
pubmed: 27583651
doi: 10.1016/j.jalz.2016.07.005
Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063–1076 (2019).
pubmed: 30753379
pmcid: 6439328
doi: 10.1093/brain/awz019
Tosun, D. et al. Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer’s disease clinical trial cohort. Alzheimers Dement. 12, 977–986 (2016).
pubmed: 27109039
doi: 10.1016/j.jalz.2016.03.009
Grubeck-Loebenstein, B. et al. Immunosenescence and vaccine failure in the elderly. Aging Clin. Exp. Res. 21, 201–209 (2009).
pubmed: 19571643
doi: 10.1007/BF03324904
Albert, M. et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain 142, 1736–1750 (2019).
pubmed: 31038156
pmcid: 6536853
doi: 10.1093/brain/awz100
Yanamandra, K. et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402–414 (2013).
pubmed: 24075978
pmcid: 3924573
doi: 10.1016/j.neuron.2013.07.046
Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
pubmed: 29653606
pmcid: 5958625
doi: 10.1016/j.jalz.2018.02.018
Molinuevo, J. L. et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 136, 821–853 (2018).
pubmed: 30488277
pmcid: 6280827
doi: 10.1007/s00401-018-1932-x
Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat. Commun. 11, 1683 (2020).
pubmed: 32246036
pmcid: 7125218
doi: 10.1038/s41467-020-15436-0
Barthelemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 12, 26 (2020).
pubmed: 32183883
pmcid: 7079453
doi: 10.1186/s13195-020-00596-4
Hanes, J. et al. Evaluation of a novel immunoassay to detect p-Tau Thr217 in the CSF to distinguish Alzheimer’s disease from other dementias. Neurology https://doi.org/10.1212/WNL.0000000000010814 (2020).
Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA https://doi.org/10.1001/jama.2020.12134 (2020).
Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain https://doi.org/10.1093/brain/awz099 (2019).
Rohrer, J. D. et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329–1336 (2016).
pubmed: 27581216
pmcid: 5047041
doi: 10.1212/WNL.0000000000003154
Benedet, A. L. et al. Plasma neurofilament light associates with Alzheimer’s disease metabolic decline in amyloid-positive individuals. Alzheimers Dement. 11, 679–689 (2019).
Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. 25, 277–283 (2019).
pubmed: 30664784
pmcid: 6367005
doi: 10.1038/s41591-018-0304-3
Ashton, N. J. et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol. Commun. 7, 5 (2019).
pubmed: 30626432
pmcid: 6327431
doi: 10.1186/s40478-018-0649-3
Mattsson, N. et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).
pubmed: 31009028
pmcid: 6583067
doi: 10.1001/jamaneurol.2019.0765
Strain, J. F. et al. Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology 91, e313–e318 (2018).
pubmed: 29959265
pmcid: 6070383
doi: 10.1212/WNL.0000000000005864
Mephon-Gaspard, A. et al. Role of tau in the spatial organization of axonal microtubules: keeping parallel microtubules evenly distributed despite macromolecular crowding. Cell. Mol. Life Sci. 73, 3745–3760 (2016).
pubmed: 27076215
pmcid: 5002045
doi: 10.1007/s00018-016-2216-z
Ng, T. S. et al. Neuroimaging in repetitive brain trauma. Alzheimers Res. Ther. 6, 10 (2014).
pubmed: 25031630
pmcid: 3978843
doi: 10.1186/alzrt239
Holleran, L. et al. Axonal disruption in white matter underlying cortical sulcus tau pathology in chronic traumatic encephalopathy. Acta Neuropathol. 133, 367–380 (2017).
pubmed: 28214960
doi: 10.1007/s00401-017-1686-x
Cedarbaum, J. M. et al. Rationale for use of the clinical dementia rating sum of boxes as a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimers Dement. 9, S45–S55 (2013).
pubmed: 22658286
doi: 10.1016/j.jalz.2011.11.002
McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011).
pubmed: 21514250
pmcid: 3312024
doi: 10.1016/j.jalz.2011.03.005
Agresti, A. & Caffo, B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am. Stat. 54, 280–288 (2000).
Baker, J. E. et al. Episodic memory and learning dysfunction over an 18-month period in preclinical and prodromal Alzheimer’s disease. J. Alzheimers Dis. 65, 977–988 (2018).
pubmed: 30103330
doi: 10.3233/JAD-180344
Grove, R. A. et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr. Alzheimer Res. 11, 47–58 (2014).
pubmed: 24359500
doi: 10.2174/1567205010666131212110148
Scheltens, P. et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res. Ther. 10, 107 (2018).
pubmed: 30309389
pmcid: 6182869
doi: 10.1186/s13195-018-0431-6
Reuter, M. et al. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 61, 1402–1418 (2012).
pubmed: 22430496
doi: 10.1016/j.neuroimage.2012.02.084
Reuter, M., Rosas, H. D. & Fischl, B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 53, 1181–1196 (2010).
pubmed: 20637289
doi: 10.1016/j.neuroimage.2010.07.020
Katz, D. et al. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics 34, 469–474 (1978).
doi: 10.2307/2530610
Lilliefors, H. W. On the Kolmogorov–Smirnov test for normality with mean and variance unknown. J. Am. Stat. Assoc. 62, 399–402 (1967).
doi: 10.1080/01621459.1967.10482916
Welch, B. L. The generalization of ‘Student’s’ problem when several different population variances are involved. Biometrika 34, 28–35 (1947).
pubmed: 20287819
Hedges, L. V. & Olkin, I. Statistical Methods for Meta-analysis. Ch. 5, B2 (Academic Press, 1985).
Chowdhury, M. Z. I. & Turin, T. C. Variable selection strategies and its importance in clinical prediction modelling. Fam. Med. Community Health 8, e000262 (2020).
pubmed: 32148735
pmcid: 7032893
doi: 10.1136/fmch-2019-000262